Business Wire

THALES

1.7.2021 09:02:13 CEST | Business Wire | Press release

Share
High-tech Solutions From Thales Optimise the Air Passenger Experience From Home to the Airport

As airports prepare for the busy summer period, they are facing a new set of challenges; dealing with the public health crisis and complying with new regulations on freedom of movement within the Schengen Area. Thales technologies enable airport operators, airlines and border officials to enhance the travel experience and increase security at four main points around the airport.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005080/en/

Secure check-in
Passengers can check in remotely from any location (home, hotel, etc.) using their airline's mobile app. The identity of each individual can then be instantly verified with face recognition software, using a combination of a selfie taken by the passenger, liveness detection and a document authenticity check. The face recognition solution checks approximately 40 points on the passenger's face and issues an alert if there is any doubt about their identity.

Based on this identity verification and facial biometrics, a temporary digital token is then created for each passenger. The passenger's face then identifies them at check-in, bag drop-off, security, passport control and the boarding gate, removing the need to show a ticket and ID card at each checkpoint. The system analyses the facial features of an individual in real time, even when they are wearing a surgical mask, and matches it to the corresponding digital identity in the system. No personal data or photos are stored; an encrypted code created during check-in is the only reference the system requires.

Passengers are identified at the boarding gate in less than a second
During boarding, passengers are instantly identified by face recognition, without needing to remove their masks or show their boarding passes. In some cases, ground staff may be required to ask a passenger to show their health pass, which can be stored in a digital ID wallet on their smartphone, to prove their vaccination status, PCR test results, etc. This mobile ID wallet protects the passengers' personal data and certifies the authenticity, validity and integrity of the health data. Health passes can also be authenticated when passengers check in before arriving at the airport.

This biometric solution for boarding gates reduces boarding times by one-third. The system erases the temporary token once the aircraft has taken off.

Smart airport operations to optimise the flow of passengers
High-tech solutions from Thales also help to manage airport operations at numerous destinations. The Group provides airport operators with smart solutions and decision support tools that help them optimise and control passenger flows inside the terminal (from the entrance to the boarding and/or arrival gate). Using high-performance algorithms, these tools and solutions enable airport operators and other stakeholders to model flight arrivals and departures as well as other airport data and run simulations. Based on those simulations, they can anticipate possible travel disruptions (late or cancelled flights) and adjust resource availability on the ground to improve the passenger experience and reduce waiting times.

New border kiosks to simplify passport control for non-European nationals
Under the new requirements for member states of the Schengen Area, non-European nationals arriving in France will soon be able to use Thales's self-service border kiosks to pre-register their identity, including their biometric data (fingerprint and facial biometrics), in less than one minute.

Pre-registration offers time savings of 30% at passport control. The system software is optimised for ultra-rapid document authentication and fraud detection. Several ports of entry (airports, ports, train stations) are due to be equipped with Thales’ border kiosks between now and May 2022.

"For several decades, Thales has been helping to manage and secure sensitive infrastructure like stations, sports arenas and other major cultural venues. With its expertise in new technologies such as AI, deep learning and biometrics, boosted by the acquisition of Gemalto in 2019, Thales is in a position to provide airports and their ecosystems with new ways to increase operational efficiency, better protect the health and safety of passengers and enhance the travel experience. Thales technologies offer secure solutions that simplify the passenger experience while guaranteeing that personal data is protected and managed with complete transparency." Philippe Keryer, Executive Vice President, Strategy, Research and Technology, Thales

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defence, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Market page

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye